Search Results

Now showing 1 - 10 of 252
  • Publication
    TestArticle2
    (2018-05-17) Eens, Marcel ; De Wael, Karolien ; Medicine and Health Sciences ; Anaesthesiology
  • Publication
    TestArticle3
    (2018-05-17) De Wael, Karolien ; Anaesthesiology
  • Publication
    TestBook1
    (2018-05-17) Eens, Marc ; Vercauteren, Marcel ; De Wael, Karolien ; Anaesthesiology ; Abdominal and Paediatric Surgery
  • Publication
    TestBook2
    (2018-05-17) Eens, Marcel ; Medicine and Health Sciences
  • Publication
    TestBook3
    (2018-05-17) Vercauteren, Marcel ; De Wael, Karolien ; Abdominal and Paediatric Surgery ; Anaesthesiology
  • Publication
    TestTheses1
    (2018-05-17) Eens, M. ; Vercauteren, Marcel ; De Wael, K. ; Anaesthesiology ; Abdominal and Paediatric Surgery
  • Publication
    TestTheses2
    (2018-05-17) Medicine and Health Sciences ; Abdominal and Paediatric Surgery ; Eens, Marcel ; Vercauteren, Marcel ; De Wael, Karolien ; Abdominal and Paediatric Surgery
  • Publication
    TestTheses3
    (2018-05-17) Eens, Marcel ; De Wael, Karolien ; Anaesthesiology ; Medicine and Health Sciences
  • Publication
    Prophylactic Platelets in Dengue: Survey Responses Highlight Lack of an Evidence Base
    (2012-06-01) Simmons, Cameron
    Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents were asked that their answers reflected what they would do if they were the treating physician. We received responses from 306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key question in the clinical management of patients with dengue.
  • Publication
    Corticosteroids for Dengue - Why Don't They Work?
    (2013-12-01) Simmons, Cameron
    BACKGROUND: Dysregulated immune responses may contribute to the clinical complications that occur in some patients with dengue. FINDINGS: In Vietnamese pediatric dengue cases randomized to early prednisolone therapy, 81 gene-transcripts (0.2% of the 47,231 evaluated) were differentially abundant in whole-blood between high-dose (2 mg/kg) prednisolone and placebo-treated patients two days after commencing therapy. Prominent among the 81 transcripts were those associated with T and NK cell cytolytic functions. Additionally, prednisolone therapy was not associated with changes in plasma cytokine levels. CONCLUSION: The inability of prednisolone treatment to markedly attenuate the host immune response is instructive for planning future therapeutic strategies for dengue.